Cited 2 times in
Concomitant t(3;3)(q21;q26), trisomy 19, and E255V mutation associated with imatinib mesylate resistance in chronic myelogenous leukemia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박태성 | - |
dc.contributor.author | 송재우 | - |
dc.contributor.author | 이경아 | - |
dc.contributor.author | 정준원 | - |
dc.contributor.author | 최종락 | - |
dc.date.accessioned | 2015-04-24T16:35:58Z | - |
dc.date.available | 2015-04-24T16:35:58Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0165-4608 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/103817 | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 46~48 | - |
dc.relation.isPartOf | CANCER GENETICS AND CYTOGENETICS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Amino Acid Substitution/genetics | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use | - |
dc.subject.MESH | Base Sequence | - |
dc.subject.MESH | Benzamides | - |
dc.subject.MESH | Chromosomes, Human, Pair 19* | - |
dc.subject.MESH | Chromosomes, Human, Pair 3* | - |
dc.subject.MESH | Drug Resistance, Neoplasm/genetics* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Glutamic Acid/genetics | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Imatinib Mesylate | - |
dc.subject.MESH | Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis | - |
dc.subject.MESH | Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy | - |
dc.subject.MESH | Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics* | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mutation, Missense | - |
dc.subject.MESH | Piperazines/therapeutic use | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Pyrimidines/therapeutic use | - |
dc.subject.MESH | Translocation, Genetic* | - |
dc.subject.MESH | Trisomy* | - |
dc.subject.MESH | Valine/genetics | - |
dc.title | Concomitant t(3;3)(q21;q26), trisomy 19, and E255V mutation associated with imatinib mesylate resistance in chronic myelogenous leukemia | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Tae Sung Park | - |
dc.contributor.googleauthor | June-Won Cheong | - |
dc.contributor.googleauthor | Soo Jeong Kim | - |
dc.contributor.googleauthor | Kyung Woo Lee | - |
dc.contributor.googleauthor | Jaewoo Song | - |
dc.contributor.googleauthor | Kyung-A Lee | - |
dc.contributor.googleauthor | Borum Suh | - |
dc.contributor.googleauthor | Sungwook Song | - |
dc.contributor.googleauthor | Jong Rak Choi | - |
dc.identifier.doi | 10.1016/j.cancergencyto.2008.11.012 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01725 | - |
dc.contributor.localId | A02054 | - |
dc.contributor.localId | A02647 | - |
dc.contributor.localId | A03729 | - |
dc.contributor.localId | A04182 | - |
dc.relation.journalcode | J00443 | - |
dc.identifier.eissn | 1873-4456 | - |
dc.identifier.pmid | 19264234 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0165460808006985 | - |
dc.contributor.alternativeName | Park, Tae Sung | - |
dc.contributor.alternativeName | Song, Jae Woo | - |
dc.contributor.alternativeName | Lee, Kyung A | - |
dc.contributor.alternativeName | Cheong, June Won | - |
dc.contributor.alternativeName | Choi, Jong Rak | - |
dc.contributor.affiliatedAuthor | Park, Tae Sung | - |
dc.contributor.affiliatedAuthor | Song, Jae Woo | - |
dc.contributor.affiliatedAuthor | Lee, Kyung A | - |
dc.contributor.affiliatedAuthor | Cheong, June-Won | - |
dc.contributor.affiliatedAuthor | Choi, Jong Rak | - |
dc.citation.volume | 190 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 46 | - |
dc.citation.endPage | 48 | - |
dc.identifier.bibliographicCitation | CANCER GENETICS AND CYTOGENETICS , Vol.190(1) : 46-48, 2009 | - |
dc.identifier.rimsid | 36715 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.